STOCK TITAN

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Unicycive Therapeutics (UNCY) reported third-quarter results and an FDA target action date of March 25, 2027, for oxylanthanum carbonate (OLC). The FDA accepted the resubmitted new drug application in October following a June 2026 Complete Response Letter citing manufacturing-vendor deficiencies, without requesting additional clinical data. Approval remains pending.

Third-quarter net loss widened to $6.997 million from $6.011 million a year earlier, while loss per share narrowed to $0.25 from $0.33. Research and development expense fell to $2.246 million; general and administrative expense rose to $6.595 million. Cash, cash equivalents and marketable securities totaled approximately $59 million at September 30, 2026. Unicycive expects funding beyond 2027, including a potential OLC launch, and plans commercial-leadership hires in the first quarter of 2027. Separate OLC reimbursement remains conditional on FDA approval and CMS eligibility confirmation.

Loading...
Loading translation...
8 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.OLC application resubmission accepted by FDA, with a March 25, 2027 target action date.
  • Moderate pointJune 2026 FDA response raised no clinical efficacy or safety concerns and requested no additional data.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Liquidity totaled approximately $59 million at September 30, 2026; Unicycive expects runway beyond 2027, including potential launch costs.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.OLC could receive two years of separate reimbursement at 100% of average sales price, subject to FDA approval and CMS confirmation.
  • Minor pointThird-quarter R&D expense fell to $2.246 million from $2.964 million a year earlier.
3 minor points
  • Minor pointThird-quarter other income rose to $1.844 million from $1.331 million a year earlier, primarily reflecting warrant revaluation.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Commercial preparations include planned leadership hires in first-quarter 2027 and sales-force hiring if OLC receives approval.
  • Minor point. Forward-looking: it has not happened yet and may not happen.CMS finalized a $12.85 per-treatment binder-funding addition effective January 1, 2027; Unicycive sees favorable potential launch conditions.

Negative

  • Moderate pointThird-quarter net loss widened to $6.997 million from $6.011 million; loss per share narrowed to $0.25 from $0.33.
  • Moderate pointOLC approval remains subject to FDA review following manufacturing-vendor deficiencies cited in the June 2026 response.
  • Moderate pointCommon shares outstanding rose to 29,110,352 at September 30, 2026, from 22,114,245 at December 31, 2025.
  • Minor pointThird-quarter G&A expense rose to $6.595 million from $4.378 million, including $1.4 million more in launch preparation.
  • Minor point. Forward-looking: it has not happened yet and may not happen.New manufacturing vendor pre-approval inspection remains uncertain; Unicycive does not know whether FDA will require one.
  • Minor pointOLC reimbursement eligibility remains subject to FDA classification and applicable CMS requirements.

News Explained

OLC could get two years of reimbursement at 100% of average sales price alongside binder base funding, subject to FDA approval and CMS eligibility.

The third-quarter balance sheet reports 29,110,352 common shares outstanding on September 30, 2026, versus 22,114,245 on December 31, 2025; an unchanged shareholding therefore represented a smaller fraction of the company.

CMS set a $12.85-per-treatment addition to dialysis providers’ phosphate-binder base rate effective January 1, 2027; separately, OLC could qualify for two years of reimbursement at 100% of average sales price if the FDA approves it and CMS confirms TDAPA eligibility.

The company says its TDAPA view rests on a Type 2 NDA classification, which the FDA alone will determine at approval; TDAPA eligibility is also subject to CMS requirements.

Key Figures

PDUFA target action date: March 25, 2027 Cash, equivalents and marketable securities: Approximately $59 million Expected cash runway: Beyond 2027 +5 more
PDUFA target action date
March 25, 2027
OLC NDA resubmission accepted; remains subject to FDA review
Cash, equivalents and marketable securities
Approximately $59 million
As of September 30, 2026
Expected cash runway
Beyond 2027
Includes anticipated increased expenses related to a potential OLC launch
Phosphate binder base-rate addition
$12.85 per treatment
Effective January 1, 2027
Potential TDAPA reimbursement
100% of average sales price for two years
Conditional on FDA approval and CMS confirmation of eligibility
R&D expense
$2.2 million vs. $3.0 million
Quarter ended September 30, 2026 vs. same period in 2025
G&A expense
$6.6 million vs. $4.4 million
Quarter ended September 30, 2026 vs. same period in 2025
Net loss attributable to common stockholders
$(7.0) million, or $(0.25) per share, vs. $(6.0) million, or $(0.33) per share
Quarter ended September 30, 2026 vs. same period in 2025

Previous Earnings Reports

1 past event · Latest: Aug 12
Same Type 1 event
  1. Aug 12

    Q2 earnings

    24h Move
    +7.8%

    June CRL cited manufacturing deficiencies; NDA resubmission remained contingent on a successful vendor inspection.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

new drug application (nda), pdufa, complete response letter (crl), cgmp, +2 more
6 terms
new drug application (nda) regulatory
"New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
pdufa regulatory
"assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027"
PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.
complete response letter (crl) regulatory
"following a Complete Response Letter (CRL) received in June 2026"
A complete response letter (CRL) is an official communication from a drug or medical device regulator saying an approval application cannot be approved in its current form and listing specific problems that must be fixed. For investors, a CRL is like a referee pausing a game and listing rule violations — it signals extra time, cost and uncertainty before a product can reach market, and it often prompts a reassessment of a company’s near-term prospects.
cgmp regulatory
"complies with current Good Manufacturing Practice (cGMP)"
cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.
tdapa financial
"eligibility for the Transitional Drug Add-on Payment Adjustment (TDAPA)"
A transitional drug add-on payment adjustment (TDAPA) is a temporary Medicare payment rule that gives hospitals higher reimbursement for newly available drugs or biologic treatments that are not yet reflected in standard outpatient payment rates. Think of it as a short-term price support that helps hospitals afford and use a new therapy while payers gather real-world cost and effectiveness data—important to investors because it can speed early adoption, stabilize initial revenue for the maker, and reduce commercial risk during the product’s launch.
505(b)(2) regulatory
"qualified for a 505(b)(2) regulatory path"
A 505(b)(2) is an FDA drug approval pathway that lets a company win approval by relying partly on existing studies or published data instead of doing all new clinical trials. Think of it like building a renovated house using the original foundation: it can be faster and less costly than a full new-drug route, reducing development risk and expense. Investors care because it can speed market entry, lower capital needs, and offer opportunities for exclusivity or competitive advantage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027

  • As of September 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $59 million, with expected runway beyond 2027, including the cost of potential OLC launch

MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”

Key Highlights & Upcoming Milestones

  • OLC NDA Resubmission: In October, the Company announced that the FDA has accepted the resubmission of its NDA for OLC and set a PDUFA target action date of March 25, 2027. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026, which cited deficiencies previously identified at the original Drug Product (DP) vendor. The June 2026 CRL did not raise concerns regarding clinical efficacy or safety data or request additional data from the Company. The resubmitted NDA remains subject to FDA review.
    • The NDA resubmission includes CMC data from a new DP manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status. The Company does not know whether the FDA will decide to conduct a pre-approval inspection of this DP vendor.
    • The original DP vendor was recently inspected by the FDA. If the FDA finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to align with the FDA on whether that determination could shorten its review timeline and potential approval.

  • Commercial Readiness: In preparation for the potential launch of OLC, Unicycive continues to advance its commercial readiness initiatives:

    • Discussions with dialysis organizations as part of the OLC launch planning.
    • The Company is in active discussions with key commercial leaders, with plans to bring them on board in the first quarter of 2027 and, if OLC is approved by the FDA, expects to hire an optimized sales force to target the physician prescriber base.
    • Unicycive is also focused on optimizing patient access across all reimbursement settings and plans to provide dedicated access and services through its UniSource™ support hub.
      On October 28, 2026, the Centers for Medicare & Medicaid Services (CMS) issued its calendar year 2027 End-Stage Renal Disease Prospective Payment System final rule, establishing permanent phosphate binder funding within the dialysis bundled payment through a $12.85 per-treatment addition to the base rate effective January 1, 2027, following the expiration of separate transitional payments for existing binders. CMS also finalized a hyperphosphatemia clinical quality measure beginning with payment year 2029, based on 2027 performance, reinforcing the importance of sustained phosphorus control. Unicycive believes that these changes create favorable commercial launch conditions for OLC, if approved. Subject to FDA approval and CMS confirmation of Transitional Drug Add-on Payment Adjustment (TDAPA) eligibility, OLC could potentially qualify for two years of separate reimbursement at 100% of average sales price while dialysis providers continue to receive the new funding for binders embedded in the base rate.
  • TDAPA Eligibility: Unicycive believes OLC meets the criteria for the TDAPA upon FDA approval:
    • OLC qualified for a 505(b)(2) regulatory path because it contains an active moiety (lanthanum) that was previously approved; however, OLC contains a new active ingredient, oxylanthanum carbonate, that was not previously approved. The Company believes this supports Type 2 NDA classification under the FDA’s Manual of Policies and Procedures 5018.2, NDA Classification Codes.
    • The determination of OLC’s NDA classification rests solely with the FDA and remains subject to the agency’s determination of NDA classification at the time of approval. The Company believes OLC, if approved, would qualify for TDAPA, subject to meeting applicable CMS requirements.

Financial Results for the Quarter Ended September 30, 2026

Research and Development (R&D) expense was $2.2 million for the quarter ended September 30, 2026, compared to $3.0 million for the three months ended September 30, 2025. The decrease was primarily driven by a $1.2 million decrease in developments costs, which was partially offset by an increase in non-cash stock-based compensation of $0.5 million.

General and Administrative (G&A) expense was $6.6 million for the quarter ended September 30, 2026, compared to $4.4 million for the three months ended September 30, 2025. The increase was primarily driven by a $0.6 million increase in non-cash stock-based compensation as well as an increase of $0.2 million in other labor costs. There was also an increase of $1.4 million related to commercial launch preparation.

Other income (expense) was $1.8 million for the quarter ended September 30, 2026, compared to $1.3 million income for the three months ended September 30, 2025, attributed primarily to the change in fair value of the Company’s warrant liability.

Net loss attributable to common stockholders, basic and diluted, for the quarter ended September 30, 2026, was $(7.0) million, or $(0.25) per share of common stock, compared to $(6.0) million, or $(0.33) per share of common stock, for the three months ended September 30, 2025. The increased net loss for the quarter ended September 30, 2026, was attributed primarily to an increase in commercial launch expenses.

Cash, cash equivalents and marketable securities were approximately $59 million as of September 30, 2026, with expected runway beyond 2027, including anticipated increased expenses related to the launch of OLC should it receive approval.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Unicycive Therapeutics
media@unicycive.com

SOURCE: Unicycive Therapeutics, Inc.



Unicycive Therapeutics, Inc.
Balance Sheets
(in thousands, except for share and per share amounts)
  As of As of
  December 31, September 30,
  2025
 2026
Assets    (Unaudited)
Current assets:      
Cash $29,198  $41,966 
Prepaid expenses and other current assets  7,692   10,187 
Marketable securities  12,071   17,006 
Total current assets  48,961   69,159 
Right of use asset, net  108   519 
Property and equipment, net  66   255 
Total assets $49,135  $69,933 
       
Liabilities and stockholders’ equity      
Current liabilities:      
Accounts payable $383  $1,030 
Accrued liabilities  1,523   3,380 
Warrant liability  16,915   12,377 
Operating lease liability - current  117   522 
Total current liabilities  18,938   17,309 
Operating lease liability - long term  -   - 
Total liabilities  18,938   17,309 
Commitments and contingencies      
Stockholders’ equity:      
Series A-2 Prime preferred stock, $0.001 par value per share - 21,388.01 Series A-2 Prime shares authorized at December 31, 2025, and September 30, 2026; 2,265 and zero Series A-2 Prime shares issued and outstanding at December 31, 2025, and September 30, 2026, respectively  -   - 
Series B-2 preferred stock, $0.001 par value per share - 50,000 Series B-2 shares authorized at December 31, 2025, and September 30, 2026; zero Series B-2 shares issued and outstanding at December 31, 2025, and September 30, 2026  -   - 
Preferred stock, $0.001 par value per share- 10,000,000 shares authorized at December 31, 2025, and June 30, 2026; zero shares issued and outstanding at December 31, 2025, and June 30, 2026  -   - 
Common stock, $0.001 par value per share - 400,000,000 shares authorized at December 31, 2025, and September 30, 2026; 22,114,245 and 29,110,352 shares issued and outstanding at December 31, 2025, and September 30, 2026, respectively  22   29 
Accumulated other comprehensive loss  (1)  (26)
Additional paid-in capital  158,001   201,988 
Accumulated deficit  (127,825)  (149,367)
Total stockholders’ equity  30,197   52,624 
Total liabilities and stockholders’ equity $49,135  $69,933 
       



Unicycive Therapeutics, Inc.
Statements of Operations and Comprehensive Loss
(in thousands, except for share and per share amounts)
(Unaudited)
  Three Months Ended September 30,
  
2025
 2026
Operating expenses:      
Research and development $2,964  $2,246 
General and administrative  4,378   6,595 
Total operating expenses  7,342   8,841 
Loss from operations  (7,342)  (8,841)
Other income (expenses):      
Interest income  279   503 
Interest expense  (15)  - 
Change in fair value of warrant liability  1,067   1,341 
Total other income (expenses)  1,331   1,844 
Net loss  (6,011)  (6,997)
Other comprehensive loss:      
Unrealized loss on marketable securities, net  -   (3)
Net comprehensive loss $(6,011) $(7,000)
Net loss per share attributable to common stockholders, basic and diluted $(0.33) $(0.25)
Weighted-average shares outstanding used in computing net loss per share  18,065,389   28,270,842 
       

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the FDA decision date for Unicycive's OLC application?

The FDA assigned March 25, 2027 as the target action date for Unicycive's resubmitted OLC application. Acceptance of the application does not constitute approval; the application remains under FDA review.

How long does Unicycive expect its cash to fund operations?

Unicycive expects its approximately $59 million in cash, cash equivalents and marketable securities at September 30, 2026, to fund operations beyond 2027. That expectation includes anticipated increased expenses for an OLC launch should the treatment receive approval.

What manufacturing information did Unicycive include in the OLC resubmission?

The resubmission includes chemistry, manufacturing and controls data from a new drug-product vendor. That vendor's facility received “No Action Indicated” status after its March 2024 FDA inspection. Unicycive does not know whether FDA will conduct a pre-approval inspection.

Could an inspection of Unicycive's original OLC manufacturer shorten the FDA review?

Unicycive plans to discuss a potentially shorter review with FDA if the original vendor's facility is found compliant with current Good Manufacturing Practice requirements. The original vendor was recently inspected, but no shorter review timeline or earlier approval has been established.

Why does Unicycive believe OLC could qualify for separate Medicare reimbursement?

Unicycive believes OLC's new active ingredient supports Type 2 new drug application classification and potential Transitional Drug Add-on Payment Adjustment eligibility. Its active moiety, lanthanum, was previously approved, but oxylanthanum carbonate was not. FDA controls the classification decision at approval, and eligibility also depends on applicable CMS requirements.

Keep reading